Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States

INTRODUCTION: Agents that inhibit sodium glucose co-transporter 2 (SGLT2), including canagliflozin and dapagliflozin, are approved in the United States for the treatment of adults with type 2 diabetes mellitus (T2DM). SGLT2 inhibition lowers blood glucose by increasing urinary glucose excretion, whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Neslusan, Cheryl, Teschemaker, Anna, Willis, Michael, Johansen, Pierre, Vo, Lien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104269/
https://www.ncbi.nlm.nih.gov/pubmed/29411292
http://dx.doi.org/10.1007/s13300-018-0371-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104269/
https://www.ncbi.nlm.nih.gov/pubmed/29411292
http://dx.doi.org/10.1007/s13300-018-0371-y

Ejemplares similares